The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 26, 2020
Filed:
Jun. 08, 2016
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Institut Gustave-roussy, Villejuif, FR;
Assistance Publique-hopitaux DE Paris, Paris, FR;
Centre Henri Becquerel, Rouen, FR;
Universite Paris Descartes, Paris, FR;
Universite Pierre ET Marie Curie (Paris 6), Paris, FR;
Universite Paris-sud, Orsay, FR;
Franck Viguie, Deuil la Barre, FR;
Olivier Bernard, Vanves, FR;
Michaela Fontenay, Paris, FR;
Christian Bastard, Ardouval, FR;
Francois Delhommeau, Antony, FR;
William Vainchenker, Paris, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
INSTITUT GUSTAVE-ROUSSY, Villejuil, FR;
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, Paris, FR;
CENTRE HENRI BECQUEREL, Rouen, FR;
UNIVERSITE PARIS DESCARTES, Paris, FR;
UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6), Paris, FR;
UNIVERSITE PARIS-SUD, Orsay, FR;
Abstract
The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.